Antivirals Study Experience

PPD leads the industry in global HIV therapeutic development and has helped clients conduct more than 125 trials on six continents. In the past five years, we have conducted Phase I-IV studies involving hepatitis B and C, human papilloma virus, parainfluenza virus type 3 and respiratory syncytial viruses, with more than 2,600 sites and 47,600 patients enrolled.¹ Our global investigator network and strong relationships ensure we secure the highest performing sites with the right patients for our clients’ programs.

1. These numbers don't include our work in the government sector, which is tracked separately.